Genprex Stock (NASDAQ:GNPX)


Chart

Previous Close

$3.69

52W Range

$3.25 - $63.00

50D Avg

$10.06

200D Avg

$13.42

Market Cap

$2.24M

Avg Vol (3M)

$787.35K

Beta

-0.73

Div Yield

-

GNPX Company Profile


Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

Mar 29, 2018

Website

GNPX Performance


Peer Comparison


TickerCompany
CMMBChemomab Therapeutics Ltd.
JAGXJaguar Health, Inc.
BDRXBiodexa Pharmaceuticals Plc
CEROCERo Therapeutics Holdings, Inc.
GRIGRI Bio, Inc.
TOVXTheriva Biologics, Inc.
CNSPCNS Pharmaceuticals, Inc.
TickerGate Footer Logo

Tickergate is an AI research agent that helps investors analyze companies, filings, and markets faster and smarter.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks